{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:09:46Z","timestamp":1793131786660,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K12 CA184746"],"award-info":[{"award-number":["K12 CA184746"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jtho.2025.11.018","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T04:50:34Z","timestamp":1764391834000},"page":"103528","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLC"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8685-3762","authenticated-orcid":false,"given":"Timothy F.","family":"Burns","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natraj Reddy","family":"Ammakkanavar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Hollebecque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe A.","family":"Cassier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Italiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Youn","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimit","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca S.","family":"Heist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustin","family":"Deming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Spira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quincy","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Sacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Chisamore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur Xintian","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel C.","family":"McNeely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Fink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey R.","family":"Oxnard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda D.","family":"Willard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonina R.","family":"Murciano-Goroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin H.","family":"Dragnev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2025.11.018_bib1","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1186\/s12885-024-13058-z","article-title":"Efficacy and safety of immune checkpoint inhibitors for advanced or recurrent endometrial cancer: a systematic review and network meta-analysis","volume":"24","author":"Huang","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtho.2025.11.018_bib2","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","article-title":"Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma","volume":"24","author":"Amaria","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2025.11.018_bib3","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.euo.2019.11.001","article-title":"Outcomes of patients with metastatic renal cell carcinoma treated with targeted therapy after immuno-oncology checkpoint inhibitors","volume":"4","author":"Graham","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.jtho.2025.11.018_bib4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12943-020-01260-z","article-title":"Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook","volume":"19","author":"Horvath","year":"2020","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jtho.2025.11.018_bib5","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.annonc.2020.01.013","article-title":"Tatton: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer","volume":"31","author":"Oxnard","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.11.018_bib6","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.jtho.2022.07.025","article-title":"OA03.06 CodeBreaK 100\/101: first report of safety\/efficacy of sotorasib in combination with pembrolizumab or atezolizumab in advanced KRAS p.G12C NSCLC","volume":"17","author":"Li","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.018_bib7","doi-asserted-by":"crossref","first-page":"709","DOI":"10.3390\/jcm12020709","article-title":"KRAS mutations in solid tumors: characteristics, current therapeutic strategy, and potential treatment exploration","volume":"12","author":"Yang","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.jtho.2025.11.018_bib8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.lungcan.2018.07.013","article-title":"KRAS-Mutant non-small cell lung cancer: from biology to therapy","volume":"124","author":"Ferrer","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2025.11.018_bib9","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.annonc.2021.06.001","article-title":"Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches","volume":"32","author":"Reck","year":"2021","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.jtho.2025.11.018_bib10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1056\/NEJMc2030638","article-title":"Distribution of KRASG12C somatic mutations across race, sex, and cancer type","volume":"384","author":"Nassar","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.018_bib11","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","article-title":"Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.11.018_bib12","doi-asserted-by":"crossref","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","article-title":"Non\u2013small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Riely","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jtho.2025.11.018_bib13","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.11.018_bib14","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1158\/1538-7445.AM2021-1259","article-title":"Abstract 1259: preclinical characterization of LY3537982, a novel, highly selective and potent KRAS-G12C inhibitor","volume":"81","author":"Peng","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2025.11.018_bib15","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for Lung Cancers with KRAS p.G12C Mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.018_bib17","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRASG12C inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.018_bib18","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(21)00605-7","article-title":"Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial","volume":"23","author":"Fakih","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.11.018_bib19","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.018_bib20","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0959-8049(20)31077-7","article-title":"4LBA late breaking - KRYSTAL-1: activity and safety of adagrasib (MRTX849) in patients with colorectal cancer (CRC) and other solid tumors harboring a KRAS G12C mutation","volume":"138","author":"Johnson","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtho.2025.11.018_bib21","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRASG12C inhibition in cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.018_bib22","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJMoa2303810","article-title":"Single-agent divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation","volume":"389","author":"Sacher","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.11.018_bib23","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41586-021-04065-2","article-title":"Diverse alterations associated with resistance to KRAS(G12C) inhibition","volume":"599","author":"Zhao","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2025.11.018_bib24","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1038\/s41591-025-03732-5","article-title":"Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer","volume":"31","author":"Skoulidis","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2025.11.018_bib25","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2025.11.018_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-026-69943-7","article-title":"Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study","author":"Murciano-Goroff","year":"2026","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2025.11.018_bib27","first-page":"S42","article-title":"OA14.06 divarasib single-agent long-term follow-up and atezolizumab combination treatment in patients with KRAS G12C-positive","volume":"19","author":"Sacher","year":"2024","journal-title":"NSCLC"},{"key":"10.1016\/j.jtho.2025.11.018_bib28","doi-asserted-by":"crossref","first-page":"S871","DOI":"10.1016\/j.annonc.2024.08.1447","article-title":"1392TiP Phase III study of pembrolizumab plus MK-1084 vs pembrolizumab plus placebo as first-line treatment for metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation and PD-L1 tumour proportion score (TPS) \u226550%: MK-1084-004","volume":"35","author":"Cobb","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.11.018_bib29","first-page":"S8","article-title":"5MO: First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced\/metastatic KRASG12C-mutated non-small cell lung cancer (NSCLC) and PD-L1 \u226550% from the phase II portion of KRYSTAL-7","volume":"20","author":"Garassino","year":"2025"},{"key":"10.1016\/j.jtho.2025.11.018_bib30","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.8605","article-title":"MK-1084 for KRAS G12C-mutated (mut) metastatic non\u2013small-cell lung cancer (mNSCLC): results from KANDLELIT-001","volume":"43","author":"Sacher","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.11.018_bib31","doi-asserted-by":"crossref","first-page":"S872","DOI":"10.1016\/j.annonc.2024.08.1449","article-title":"1394TiP KRYSTAL-7: a phase III study of first-line adagrasib plus pembrolizumab versus pembrolizumab alone in patients with advanced NSCLC with KRASG12C mutation","volume":"35","author":"Garassino","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.11.018_bib32","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS8656","article-title":"Krascendo 2: a phase III study of divarasib and pembrolizumab vs pembrolizumab and chemotherapy in patients with previously untreated, advanced or metastatic, KRAS G12C-mutated non-small cell lung cancer (NSCLC)","volume":"43","author":"Skoulidis","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.11.018_bib33","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-CT028","article-title":"Abstract CT028: a first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors","volume":"83","author":"Murciano-Goroff","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2025.11.018_bib34","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.2024.42.16_suppl.3007","article-title":"Pan-tumor activity of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in patients with KRAS G12C-mutant advanced solid tumors","volume":"42","author":"Heist","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.11.018_bib35","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.3_suppl.94","article-title":"Efficacy and safety of LY3537982, a potent and highly selective KRAS G12C inhibitor in KRAS G12C-mutant GI cancers: results from a phase 1 study","volume":"42","author":"Hollebecque","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.11.018_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237802","article-title":"Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin","volume":"15","author":"Woodhouse","year":"2020","journal-title":"PLOS One"},{"key":"10.1016\/j.jtho.2025.11.018_bib37","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1158\/2159-8290.CD-23-0467","article-title":"Quantifying the expanding landscape of clinical actionability for patients with cancer","volume":"14","author":"Suehnholz","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2025.11.018_bib38","article-title":"OncoKB: a precision oncology knowledge base","volume":"2017","author":"Chakravarty","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtho.2025.11.018_bib39","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1158\/2643-3230.BCD-20-0094","article-title":"Large-scale identification of clonal hematopoiesis and mutations recurrent in blood cancers","volume":"2","author":"Feusier","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.jtho.2025.11.018_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2022.106787","article-title":"Clonal hematopoiesis: molecular and clinical implications","volume":"113","author":"Kusne","year":"2022","journal-title":"Leuk Res"},{"key":"10.1016\/j.jtho.2025.11.018_bib41","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1158\/2159-8290.CD-22-1420","article-title":"Comutations and KRASG12C inhibitor efficacy in advanced NSCLC","volume":"13","author":"Negrao","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2025.11.018_bib42","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/1078-0432.CCR-24-2310","article-title":"Impact of co-mutations and transcriptional signatures in non-small cell lung cancer patients treated with adagrasib in the KRYSTAL-1 trial","volume":"31","author":"Negrao","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2025.11.018_bib43","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jtho.2021.10.013","article-title":"Diminished efficacy of programmed death-(ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status","volume":"17","author":"Ricciuti","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.018_bib44","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.jtho.2021.03.024","article-title":"SMARCA4 and other SWItch\/Sucrose nonfermentable family genomic alterations in NSCLC: clinicopathologic characteristics and outcomes to immune checkpoint inhibition","volume":"16","author":"Alessi","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.018_bib45","article-title":"Associations of tissue tumor mutational burden and mutational status with clinical outcomes with pembrolizumab plus chemotherapy versus chemotherapy for metastatic NSCLC","volume":"4","author":"Garassino","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jtho.2025.11.018_bib46","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.annonc.2023.01.011","article-title":"Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC","volume":"34","author":"Mok","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.11.018_bib47","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial","volume":"401","author":"de Langen","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2025.11.018_bib48","article-title":"LBA4 Preliminary safety and efficacy of adagrasib with pembrolizumab in treatment-na\u00efve patients with advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation","volume":"16","author":"J\u00e4nne","year":"2022","journal-title":"Immuno-Oncol Technol"},{"key":"10.1016\/j.jtho.2025.11.018_bib49","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.21.02885","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non-small-cell lung cancer and programmed death ligand-1 tumor proportion score \u2265 1% in the KEYNOTE-042 study","volume":"41","author":"de Castro","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.11.018_bib50","series-title":"A first-in-human Phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors [Presentation]","author":"Murciano-Goroff","year":"2023"},{"key":"10.1016\/j.jtho.2025.11.018_bib51","doi-asserted-by":"crossref","first-page":"8510","DOI":"10.1200\/JCO.2024.42.16_suppl.8510","article-title":"Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC","volume":"42","author":"Burns","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.11.018_bib52","doi-asserted-by":"crossref","first-page":"S234","DOI":"10.1016\/j.jtho.2025.09.434","article-title":"Thoele K., et al. P1.17.49 Real-world outcomes with IO and chemo-IO demonstrate unmet need for 1L KRAS G12C-mutant advanced NSCLC in the US","volume":"20","author":"Sheffield","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.11.018_bib53","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2025.11.018_bib54","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086425029363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086425029363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:28:20Z","timestamp":1778819300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086425029363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1556086425029363"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2025.11.018","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLC","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2025.11.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"103528"}}